Business Description
Ardelyx Inc
NAICS : 325412
SIC : 2834
ISIN : US0396971071
Compare
Compare
Traded in other countries / regions
ARDX.USA41X.GermanyARDX.Mexico IPO Date
2023-04-27Description
Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of innovative, first-in-class medicines that meet significant unmet medical needs. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.77 | |||||
| Equity-to-Asset | 0.43 | |||||
| Debt-to-Equity | 0.71 | |||||
| Debt-to-EBITDA | -2.14 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 1.25 | |||||
| Beneish M-Score | -0.52 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 88.2 | |||||
| 3-Year EBITDA Growth Rate | 36.1 | |||||
| 3-Year EPS without NRI Growth Rate | 34.1 | |||||
| 3-Year FCF Growth Rate | 23.4 | |||||
| 3-Year Book Growth Rate | -18.9 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 59.96 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 14-Day RSI | 0.15 | |||||
| 6-1 Month Momentum % | -21.43 | |||||
| 12-1 Month Momentum % | 60.12 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.21 | |||||
| Quick Ratio | 3.99 | |||||
| Cash Ratio | 2.98 | |||||
| Days Inventory | 129.8 | |||||
| Days Sales Outstanding | 48.6 | |||||
| Days Payable | 130.22 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -35.4 | |||||
| Shareholder Yield % | -7.25 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 86.03 | |||||
| Operating Margin % | -28.05 | |||||
| Net Margin % | -31.02 | |||||
| FCF Margin % | -40.38 | |||||
| ROE % | -41.81 | |||||
| ROA % | -21.95 | |||||
| ROIC % | -59.35 | |||||
| 3-Year ROIIC % | 41.85 | |||||
| ROC (Joel Greenblatt) % | -227.87 | |||||
| ROCE % | -20.94 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 6.23 | |||||
| PB Ratio | 9.02 | |||||
| Price-to-Tangible-Book | 9.08 | |||||
| EV-to-EBIT | -24.58 | |||||
| EV-to-EBITDA | -25.41 | |||||
| EV-to-Revenue | 5.93 | |||||
| EV-to-Forward-Revenue | 2.9 | |||||
| EV-to-FCF | -14.5 | |||||
| Price-to-Net-Current-Asset-Value | 20.11 | |||||
| Earnings Yield (Greenblatt) % | -4.07 | |||||
| FCF Yield % | -6.47 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers